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ABSTRACT
Objectives: Solid organ transplantations are among the most expensive
treatments yet relatively few investigators have reported well-
characterized and reliable information on costs. The objective here was to
compare the direct medical costs of kidney, liver, heart, and lung trans-
plantations in British Columbia (BC), Canada.
Methods: Using data from a province-wide population-based registry,
resource utilization data were collated for 1333 patients who underwent
solid organ transplantation between 1995 and 2003. Resource categories
included hospital stays, physician fees, laboratory and diagnostic testing,
and immunosuppressants. Mean costs (2003 $CDN) were derived for the
index hospitalization and each of the 2 years after hospital discharge. To
enable valid comparisons, the same costing methodology was applied to
all four programs.
Results: The mean costs of transplantation varied from $27,695 for
kidney recipients to $89,942 for lung recipients, with inpatient hospital
stays comprising the largest component. Mean costs for the ﬁrst and
second follow-up years ranged from $27,592 and $11,424 for lung recipi-
ents to $21,144 and $8086 for liver recipients. Immunosuppressants
accounted for between two-thirds and three-fourths of costs by the second
year. Within each program, variations in costs could not be accounted for
by demographic factors.
Conclusions: We observed in BC a threefold variation in mean costs of
organ transplantation procedures, with the variations between programs
diminishing during follow-up. Policymakers and decision-makers seeking
to better understand the deployment of resources for transplantation may
focus on clinical factors at the time of hospitalization and factors that
inﬂuence use and costs of immunosuppressants during the induction and
maintenance phases.
Keywords: cost of illness, decision-making, direct care health costs, trans-
plant, treatment costs.
Introduction
Over the last 50 years solid organ transplantation has developed
from a primitive medical experiment to an effective therapeutic
treatment for patients with end-organ failure [1]. Graft and
patient survival has increased for all solid organ transplants as a
result of improved patient selection criteria and timing of trans-
plantation, enhanced surgical techniques and organ preservation,
more effective antimicrobial prophylaxis, increased knowledge of
the immunologic barriers, and the advent of more potent immu-
nosuppressant medications [2,3]. Owing to these innovations
and the acceptance of patients with more complicated diseases as
candidates for transplant, there has been rapid growth in the
number of transplantations performed. According to the United
Network of Organ Sharing registry in the United States, the
annual total number of solid organ transplants increased 123%
(from 12,618 to 28,109) between 1988 and 2005 [4]. The largest
constraint on transplant activity is the need for donor organs that
exceeds the available supply in Canada [5], the United States [6],
and European countries [7].
Although solid organ transplantations are acknowledged to
be among the most resource-intensive medical and surgical pro-
cedures [8,9], there are few reliable studies that systematically
analyze the costs associated with organ transplantation [10–13].
The majority of existing publications addressing economic
matters in solid organ transplantation have assessed the cost-
effectiveness of speciﬁc treatments or management strategies, and
less attention has focused on the costs of transplantation proce-
dures or follow-up. Cost-effectiveness studies have tended to
incorporate surrogate measures of cost [10], and sometimes
excluded relevant categories of resource use [10,14]. Among
available costing studies, there has been considerable variation
between results with little exploration of the sources of variation.
For example, in a review of the ﬁnancial aspects of liver trans-
plantation [15], the estimated mean costs (1995 US$) varied
approximately twofold between the United States ($203,434)
[16] and France ($103,400), and fourfold variations have
observed for kidney transplantation (mean costs ranging between
(2000) US$121,698 in the United States [17] and (2001)
US$33,421 in Turkey [18]. Valid comparisons of the results of
these and other costing studies are hampered by the differences in
the clinical settings on which they are based, the resource cat-
egories included, the methodologies used to calculate costs, and
the time periods examined [10,19]. Comparability is also hin-
dered by treatment patterns (including candidate selection and
medical management) and inputs into this management (health-
care system costs) that differ between jurisdictions [20].
In Canada, the Canadian Council for Donation and Trans-
plant (CCDT) was established in 2001 “to coordinate federal,
provincial and territorial activities relating to organ donation and
transplantation” and “to monitor the performance in Canada
against other jurisdictions” [21]. To fulﬁll this mandate, the
CCDT and other decision-makers and policymakers require well-
characterized and reliable information on costs of transplant. To
date, only four groups of investigators have published estimates of
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the cost of solid organ transplants in Canada, including kidney
[22], lung [20], and liver [23,24]. Two of these studies focused on
direct medical costs [23,24], whereas the two other studies
adopted a broader perspective by including patient-borne costs
[20,22]. An understanding of the directmedical costs generated by
transplant recipients is important because it provides a basis for
health planners to allocate budgets and to reimburse speciﬁc
categories of expenditure. Such an understanding enables policy-
makers to make more informed choices between programs [25],
particularly when combined with estimates of the effectiveness of
treatments.
The objective of this study was to estimate the direct medical
costs of kidney, liver, heart, and lung transplantation from the
date of transplant up to 2 years post-transplantation for the
province of British Columbia (BC), Canada. The study was based
on data from a provincial registry of all transplantations per-
formed in BC from 1995 to 2003. Patients’ service use during the
hospitalization for the transplantation and each of the 2 years
after hospital discharge were compiled and assigned costs sepa-
rately. To enable valid comparisons, the same costing methodol-
ogy was applied to the four types of organ grafts.
Methods
The BC Transplant Society Data
BC currently has the only integrated delivery system for organ
transplant services in Canada, organized under the auspices of
a publicly funded, not-for-proﬁt agency known as the BC
Transplant Society. Established in 1986, the BC Transplant
Society has a mandate to coordinate, fund, and monitor all
solid organ transplant services in BC, including the establish-
ment of quality standards, pretransplant assessment, transplant
surgery, follow-up care, and the distribution of immunosup-
pressant medications. These services and supplies are paid for
through BC Transplant Society’s global budget funded by the
provincial ministry of health. The integrated delivery system
means that research on organ transplantation in BC can be
done in a population-based fashion and is therefore not prone
to selection biases that may arise in studies in which only a
subset of the target population is included, such as single-
center, clinic-based studies.
The primary mechanism for monitoring the transplant system
in BC consists of a provincial registry that compiles records of all
persons receiving a solid organ transplant. For the purpose of this
study the BC Transplant Society provided records on 1333 solid
organ transplants performed on persons aged 20 years or older in
BC from 1995 to 2003. The records for recipients of single- and
double-lung implants were combined because of the compara-
tively small number of patients receiving a double-lung implant
(n = 25). Recipients of a combined heart-and-lung transplanta-
tion were excluded because of the small number (n = 3).
Calculation of Direct Costs
The perspective taken was that of the BC Ministry of Health, a
third-party payer, and included only direct medical costs. This
viewpoint was chosen because extensive individual-level data
were available on health-care resource use, allowing direct
medical costs to be estimated with accuracy and precision.
Patients who underwent transplantation were followed lon-
gitudinally from the time of the transplantation (the date of
hospital admission through to date of discharge) until the end of
the second year of follow-up (2 years from date of discharge).
Direct medical costs were calculated for three distinct periods: 1)
the care received during the index hospitalization for transplant;
the care received in the 2) ﬁrst year after transplantation; and 3)
second year after transplantation. Some resources could be
expended during a period of time longer than a day, and these
were assigned to the treatment year in which they were charged.
Hospitalization costs were attributed based on the date of dis-
charge and medication costs were based on the date of dispen-
sation. All other costs were assigned based on the date they were
expended.
Direct medical costs were estimated using both “bottom-up”
and “top-down” approaches [26]. Top-down costing involves
dividing the total expenditure for a given set of patients by the
total number of services provided to estimate the average unit
cost. This average unit cost is often expressed as an average per
diem (or daily cost), with the average per diem applied to the
measured volume of services provided to the patients under study
to estimate their direct cost (e.g., ward-speciﬁc average per diems
multiplied by patients’ length of hospital stay [LOS] within each
ward gives an estimate of their direct cost of stay). Bottom-up
costing involves identifying the speciﬁc resources that were used
by the patients under study and then valuing each resource
component using an appropriate unit cost (rather than applying
an average per diem). The costs of hospitalizations were calcu-
lated using the top-down approach; all other direct costs were
calculated using the bottom-up approach. Discounting using a
3% interest rate was used to adjust costs relating to the post-
transplantation periods to present value at time of the index
transplant hospitalization [27].
The costs of organ procurement included only the physician
fees for explanation and excluded care of living donors. In BC,
like in other Canadian jurisdictions, organ procurement organi-
zations are not reimbursed for donor organs.
Unit costs were obtained for inpatient hospital stays (with
intensive care unit [ICUs] and nursing wards separated), physi-
cian care in and out of hospital, laboratory and diagnostic
testing, and immunosuppressant medications (Table 1). All unit
costs were converted to 2003 $CDN using health expenditure
inﬂators for Canada [28], and these unit costs were applied to the
volume of services provided to each patient. The cost estimates
derived by this method can be interpreted as the amounts that
would have been incurred had all organ recipients received their
transplant in 2003.
The costs of a hospital stay are substantially higher for trans-
plant patients compared with other types of hospitalized
patients. Therefore, we used an unpublished report commis-
sioned by the BC Transplant Society [29] that estimated the
average per diems of a hospital stay after surgical implantation of
a new graft in one BC hospital. These average per diems included
nursing personnel, all medications in hospital (including immu-
nosuppressants), medical supplies, and overhead costs. That
report was also used to cost the ancillary inpatient services used
by patients during transplantation, including the cost of operat-
ing rooms, medications, diagnostic imaging, laboratory services,
allied health professionals, and support services. For the post-
transplantation periods, recipients who are hospitalized have
resource utilization similar to that of other inpatients so we used
published per diems of a hospital stay estimated in a tertiary care
center in Vancouver [30]. These average per diems were esti-
mated across all patients requiring hospitalization, irrespective of
whether they received a transplant, and provide fully allocated
costs of all activities performed in hospital [31], including ancil-
lary inpatient services.
The amounts paid to physicians involved in the treatment and
care of transplant patients were determined using a schedule
determined by the Provincial Health Services Authority for
surgical and in-hospital follow-up care provided by medical
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specialists [32] and by the BC Medical Services Plan for post-
transplantation follow-up care [33]. The costs of immuno-
suppressants administered to outpatients were calculated based
on actual purchase prices with a mark-up for the pharmacy
department [34]. The facility operating costs for outpatient care
were sourced from the BC Transplant Society, whereas the tests
and biopsies performed on outpatients were given a cost indi-
vidually using the fee schedule from the BCMedical Services Plan
(more information can be found in the Web-based supporting
information Table 1 [URL provided at the end of the article]).
Results were calculated for three time periods (1995 to 1997,
1998 to 2000, and 2001 to 2003).
Results
Recipient Characteristics
Between 1995 and 2003 in BC, 876 patients received a kidney
graft, 257 a liver graft, 133 a heart graft, and 67 a lung graft
(Table 2). The number of kidney transplantations increased
during the three periods and there was no consistent trend for the
other programs. The age of patients who received a transplant
ranged from 20 to 69 years, with the proportion aged 50 years or
older increasing between the ﬁrst and last period for kidney, liver,
and heart transplantations, and decreasing for lung grafts. More
men than woman underwent transplant, with the percentage of
male patients varying from 53% for liver grafts to 80% for heart
grafts. Kidney recipients showed the highest survival rates at
discharge (99%) and during the 2-year post-transplantation
period (94%), whereas patients receiving lung grafts exhibited
the lowest survival at discharge (85%) and at 2 years (70%). The
demographic characteristics of the study population were gener-
ally comparable with those observed in European [19,35] and US
[13,16] populations.
Resource Use
Over the three calendar periods there was a clear pattern of
decline in the length of nursing ward stay across the four types
of transplantations, although these declines were not always
reﬂected in the total LOS (Table 3). Both renal and heart trans-
plant recipients showed a decline in the mean total LOS, with the
majority of this attributable to a fall in the length of nursing ward
stay. In contrast, the mean total LOS for liver transplant recipi-
ents remained stable, whereas the mean total LOS for lung trans-
plant recipients increased. The high total LOS for lung transplant
recipients was attributable to a marked rise in the time spent in
ICU; this was despite the fact that recipients of lung transplants
exhibited the largest decline in duration of nursing ward stay.
Table 2 Characteristics of persons undergoing solid organ transplant in British Columbia, 1995–2003
Program Variable Categories 1995 to 1997 1998 to 2000 2001 to 2003 All periods
Kidney Number of subjects 279 287 310 876
Age (year), % 20–29 9 12 11 11
30–39 22 18 20 20
40–49 31 27 22 26
50–59 22 27 28 26
60–69 16 16 19 17
Sex, % Women 40 43 40 41
Survival, % At discharge 99 99 100 99
At 1 year 96 96 99 97
At 2 years 95 96 98 97
Liver Number of subjects 85 79 93 257
Age (year), % 20–29 2 3 5 4
30–39 12 10 6 9
40–49 44 34 26 34
50–59 26 42 42 37
60–69 16 11 20 16
Sex, % Women 40 32 47 40
Survival, % At discharge 92 90 92 91
At 1 year 94 94 91 93
At 2 years 88 87 90 89
Heart† Number of subjects 50 37 46 133
Age (year), % 20–29 2 5 7 5
30–39 6 5 9 7
40–49 24 30 4 19
50–59 46 35 39 41
60–69 22 24 41 29
Sex, % Women 22 27 20 23
Survival, % At discharge 90 89 98 92
At 1 year 93 91 98 94
At 2 years 91 91 96 93
Lung* Number of subjects 25 15 26 67
Age (year), % 20–29 12 13 12 12
30–39 15 20 12 15
40–49 15 20 23 19
50–59 38 27 38 36
60–69 19 20 15 18
Sex, % Women 46 47 27 39
Survival, % At discharge 88 87 81 85
At 1 year 83 85 95 88
At 2 years 70 85 86 79
*Single- and double-lung combined.
†Heart–lung excluded.
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In the post-transplantation periods, the mean number of per-
patient hospitalizations was generally less than one, with hospi-
talizations lower in the second post-transplantation year than the
ﬁrst year after transplantation (data not shown). Patients receiv-
ing a lung graft were more likely to be hospitalized for a com-
plication in the ﬁrst 2 years after transplantation than other
transplant patients. Renal transplant recipients had more clinic
visits than those from other transplant programs in both post-
transplantation periods, with the number of visits in the ﬁrst and
second year after transplantation rising during the study period
for kidney and lung recipients and falling for heart and liver
recipients.
Direct Medical Costs
Mean total costs and standard deviations for the four different
types of organ transplantations are presented in tabular form in
the Web-based supporting information (URL provided at the end
of the article) for the index hospitalization (supporting informa-
tion Table 2) and two post-transplantation years (supporting
information Tables 3 and 4). Throughout all the periods there
was a threefold variation in the mean total cost of the index
hospitalization, ranging from $89,942 for lung recipients,
through $72,396 for liver recipients, and $66,516 for heart
recipients to $27,695 for kidney recipients (Fig. 1). The cost of
inpatient hospital stays, and particularly ancillary inpatient ser-
vices that contributed between 50% and 70% of the mean total
cost of the transplantation, comprised the largest component in
the index hospitalization. Declines in nursing ward LOS caused a
fall in the mean cost of nursing ward and ancillary inpatient
services for both kidney and heart transplantations, with a cor-
responding decline in mean total cost. An increase in the length
of ICU stay caused a rise in the mean cost of ICU and ancillary
inpatient services for lung recipients, resulting in an increase in
mean total cost. The mean total cost of liver transplantations
remained comparatively stable. The high cost of lung transplan-
tations can be explained by the fact that recipients have the
highest total length of inpatient stay and spend up to 40% of
their stay in ICU, where the unit cost of an inpatient day is nearly
four times as high as the unit cost of an inpatient day in a nursing
ward.
The variability between the programs in the mean follow-up
costs declined during the two post-transplantation years. In the
ﬁrst post-transplantation year, the mean total costs of follow-up
were $21,552 for kidney recipients, $27,593 for lung recipients,
$22,588 for heart recipients, and $21,146 for liver recipients
(Fig. 2a). By the second post-transplantation year mean total
costs were about half the amount of ﬁrst-year costs and ranged
from $11,426 for lung recipients to $8090 for liver recipients
(Fig. 2b), with medications accounting for between two-thirds
and three-fourths of the costs.
The growth in ﬁrst-year follow-up costs can be attributed to
increased spending on hospitalization and medication, and
second-year follow-up costs rose for kidney and lung recipients
because of higher medication costs, whereas it fell for liver recipi-
ents because of reduced spending on outpatient care and medi-
cation. The relationship between recipient postoperative survival
and mean treatment costs was strongest for lung transplanta-
tions, with a positive correlation coefﬁcient between survival
rates and mean follow-up treatment costs. This may indicate that
an increase in the survival among “higher risk patients” was
associated with higher follow-up treatment costs.
From the date of organ replacement up to the end of the
second year of follow-up, the combined mean total cost ranged
from $127,501 for lung recipients to $100,552 for liver recipi-
ents, $97,662 for heart recipients and $59,085 for kidney recipi-
ents (Fig. 3). The cost of the index hospitalization contributed to
about 70% of the combined total cost of lung, heart, and liver
transplantations, and 45% of the combined cost of kidney trans-
plantations. Lung transplant recipients were the most costly
group to treat and exhibited the largest increase in combined
mean total cost throughout the study period, whereas heart
transplant patients experienced a fall in combined cost. In both
cases the majority of the cost changes occurred in the index
hospitalization. The combined mean total cost of treating kidney
and liver transplant recipients showed only a modest increase.
Demographic Predictors of Transplant Costs
Multivariate regression models were developed to assess the
association between patient demographic characteristics at time
of transplantation and the direct medical costs incurred by trans-
plant patients. We observed three relatively weak and statistically
signiﬁcant trends (data not shown): 1) the recipient’s age was
signiﬁcantly associated with higher costs in the index kidney
hospitalizations; 2) men undergoing a lung transplant had higher
follow-up costs than women in the ﬁrst year of follow-up; and 3)
men undergoing a kidney transplant had lower costs in the ﬁrst
Table 3 Mean (SD) length of stay (LOS) in hospital during the index hospitalization, British Columbia, 1995–2003
Program Period LOS in ICU LOS in nursing ward Total LOS
Kidney 1995–1997 0.2 (0.1) 11.9 (0.5) 12.1 (0.5)
1998–2000 0.1 (0.1) 10.1 (0.4) 10.2 (0.4)
2001–2003 0.1 (0.1) 8.6 (0.2) 8.7 (0.2)
All periods 0.1 (0.1) 10.2 (0.2) 10.3 (0.2)
Liver 1995–1997 4.9 (0.9) 18.8 (2.2) 23.7 (2.6)
1998–2000 5.9 (1.6) 16.9 (2.4) 22.8 (3.2)
2001–2003 5.8 (1.0) 18.2 (1.7) 24.0 (2.2)
All periods 5.5 (0.7) 18.0 (1.2) 23.5 (1.5)
Heart 1995–1997 7.1 (1.5) 16.9 (2.2) 24.0 (2.8)
1998–2000 7.9 (2.6) 9.1 (1.1) 17.0 (2.7)
2001–2003 6.5 (1.0) 12.9 (3.0) 19.3 (3.3)
All periods 7.1 (0.1) 13.3 (1.4) 20.4 (1.7)
Lung 1995–1997 5.0 (1.0) 20.8 (1.6) 25.8 (1.9)
1998–2000 13.7 (5.1) 17.0 (2.7) 30.7 (5.8)
2001–2003 14.5 (3.3) 15.5 (1.8) 30.0 (3.4)
All periods 10.6 (1.8) 17.9 (1.1) 28.5 (2.0)
ICU, intensive care unit.
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year of follow-up. Given the lack of a framework to contextual-
ize these results, the number of statistical tests performed that
increased the likelihood of a spurious ﬁnding, and the relatively
small amount of variation that was explained, we suggest that
clinical factors at transplantation are likely to be much stronger
inﬂuences on costs of transplantation than demographic factors.
Discussion
Applying standardized costing methodology to a population-
based registry of solid organ transplant recipients in BC, we
observed a threefold variation in the mean costs of the transplan-
tation for lung and kidney recipients, with liver and heart
transplant recipients intermediate in mean costs. For all four
programs, inpatient hospital stays were the main components of
costs in the index hospitalization. Declines in the mean length of
nursing ward stay led to a fall in the cost of kidney and heart
transplantations, whereas an increase in the mean length of ICU
stay caused a rise in the cost of lung transplantations. The 2 years
after transplantation exhibited substantially lower mean
treatment costs and less variability in costs between programs.
Second-year follow-up costs were about half the size of ﬁrst-year
costs, which is likely because of the patients having more com-
plications and requiring a higher level of monitoring in the period
subsequent to transplantation. Growth in ﬁrst-year follow-up
costs was attributable to increased spending on hospitalization
and immunosuppressant medications, and second-year follow-up
costs rose for kidney and lung recipients because of higher medi-
cation costs, whereas it fell for liver recipients because of reduced
spending on outpatient care and medication. Immunosuppres-
sant medications were the largest contributor to follow-up costs,
accounting for between two-thirds and three-fourths of the mean
total cost. Improvements in patient survival rates may have
contributed positively to the growth in follow-up treatment
costs, particularly for lung transplant recipients.
In contrast to the United States, organ procurement organi-
zations in Canada are not reimbursed directly for donor organs.
In the United States, a sizeable amount is charged for the organ,
and these charges show wide variability: in an audit of 13 organ
acquisition cost centers in the United States between 1997 and
2003, kidney acquisition costs (US$) ranged between $22,097
and $59,811 (median $37,869), and liver acquisition costs
ranged between $17,679 and $46,604 (median $33,676) [36].
For the kidney program, the information reported on costs
is relevant to other programs within Canada. The management
of chronic renal failure is coordinated between regions, with
renal transplantation being the treatment of choice; as a con-
sequence, almost 40% of patients with renal failure in Canada
are now maintained with a functioning transplant, and the role
of living donor transplantation continues to expand [37]. The
use of potent and selective immunosuppressants has increased
the success and safety of renal transplantation during the
period of observation; death and graft loss are now uncommon
during the ﬁrst 2 years and complications have diminished in
frequency and severity, leading to improvements in both quality
of life and overall cost-effectiveness [38]. This evolution is
reﬂected in the health costs reported here, with a decline in
hospitalization time (Table 3) and costs for the transplant pro-
cedure (Fig. 1), but an increase in maintenance immunosuppres-
sant costs (Fig. 2). Attempts to minimize the latter by more
individualized therapy are ongoing, but demand to a large
extent more detailedbiomarkers of the recipient immune status
to avoid delayed graft rejection.
For the liver program, attempts at standardization for the
allocation of deceased donor livers for liver transplant candidates
have generally utilized the model for end-stage liver disease score
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[39]. As a result, similar to liver programs across Canada, the BC
liver program has tended to implant the sickest patients, deem-
phasizing waiting times as the predominant prioritizing factor.
Patient admission based on disease severity has consequences for
the length of hospitalization, with sicker patients likely to have
higher lengths of stay. This was evident in the index transplan-
tation in which liver transplant recipients experienced an increase
in their mean length of ICU stay (Table 3). Interestingly, the
combined mean cost for liver transplant throughout the study
period did not increase substantially (rising by about $2500),
largely because the increased length of ICU stay was partially
offset by a decline in the length of nursing ward stay.
For the heart program, the mean cost of the index hospital-
ization fell because of a reduction in the length of hospital stay
a
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(Table 3), whereas mean ﬁrst-year follow-up costs rose because
of higher medication costs (Fig. 2a). The decrease in the length of
stay coincided with the hiring of a clinical nurse specialist to aid
in teaching and patient support to facilitate earlier patient dis-
charge from hospital. The growth in medication costs through-
out the study period is because of the initiation of a newer, more
expensive immunosuppressant protocol.
For the lung program, the costs of transplantation were typi-
cally high. These patients are often severely compromised when
they come to transplant, and may have prolonged requirements
for mechanical ventilation in a setting of primary allograft dys-
function. Both factors contribute to a high ICU requirement in
the index hospitalization, with lung transplant recipients staying
longer in ICU (Table 3), and experiencing higher ICU costs
(Fig. 1) than other organ recipients. Lung transplant recipients
are also typically more prone to acute organ rejection, necessi-
tating increased post-transplantation costs related to hospital
stays (Fig. 2a and 2b) and medications (Fig. 2b).
Few studies have estimated the direct costs of organ transplan-
tation,making the number of Canadian studies withwhichwe can
compare our ﬁndings sparse. Nevertheless, to put the estimates
from the present study into perspective, we have summarized the
available estimates on the costs of organ transplantation in
Canada (Table 4). A direct comparison of cost estimates from our
study with those derived from other Canadian studies is difﬁcult,
although some of the trends are worth mentioning. For example,
liver transplant recipients are universally among the most expen-
sive group to treat. In Ontario the mean cost of liver transplanta-
tion was estimated to be $78,960 for the index hospitalization,
and $15,159 averaged throughout 2 years after transplantation
[24]. This compares favorably with our own estimates of $73,993
and $13,614 (averaged throughout 2 years), respectively. Another
Canadian study calculated the mean cost of the index hospitali-
zation to be as high as $103,917, although this study focused
solely on liver transplant recipients suffering from a chronic
hepatitis B infection [23]. Similarly, post-transplantation costs
reported elsewhere were typically much lower than costs in the
index hospitalization. For example, the reduction in post-
transplantation costs relative to costs in the index hospitalization
are parallel andmore extreme than those observed inQuebec [20].
The differences reﬂect the fact that the Quebec study also included
lost productivity costs, and these costs may be substantial when
follow-up is characterized by recurrent illness episodes.
There were several limitations to the current study. First, we
were unable to estimate costs before transplantation, which
included the cost of diagnostic testing, assessment for transplan-
tation, and managing complications in patients waiting for an
organ. For many of the transplant programs these pretransplan-
tation costs may be substantial [40]. Second, we did not include
the costs associated with donors. Although in BC there is no
charge for the organ, we did not include costs associated with
maintaining, and transporting organs from cadaveric sources
and, in the case of living donation, of caring for the donor. Third,
although considerable effort was expended to derive accurate
average per diems, these unit costs may not have reﬂected actual
resource use [25,26]. The impact may be greatest for patients
treated in hospital with perioperative medications having high
acquisition costs such as monoclonal antibodies. Though they
$0
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
$70,000
$80,000
$90,000
$100,000
$110,000
$120,000
$130,000
$140,000
$150,000
30-100200-899179-5991
Calendar period
C
o
st
s 
(2
00
3 
$C
D
N
)
Combined cost Transplantation phase Follow-up, year 1 Follow-up, year 2
($27,695, All periods)
($20,924, All periods)
($10,466, All periods)
($59,085, All periods)
$0
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
$70,000
$80,000
$90,000
$100,000
$110,000
$120,000
$130,000
$140,000
$150,000
30-100200-899179-5991
Calendar period
C
o
st
s 
(2
00
3 
$C
D
N
)
Combined cost Transplantation phase Follow-up, year 1 Follow-up, year 2
($72,396, All periods)
($20,530, All periods)
($7,626, All periods)
($100,552, All periods)
$0
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
$70,000
$80,000
$90,000
$100,000
$110,000
$120,000
$130,000
$140,000
$150,000
30-100200-899179-5991
Calendar period
C
o
st
s 
(2
00
3 
$C
D
N
)
Combined cost Transplantation phase Follow-up, year 1 Follow-up, year 2
($66,516, All periods)
($21,930, All periods)
($9,216, All periods)
($97,662, All periods)
$0
$10,000
$20,000
$30,000
$40,000
$50,000
$60,000
$70,000
$80,000
$90,000
$100,000
$110,000
$120,000
$130,000
$140,000
$150,000
30-100200-899179-5991
Calendar period
C
o
st
s 
(2
00
3 
$C
D
N
)
Combined cost Transplantation phase Follow-up, year 1 Follow-up, year 2
($89,942, All periods)
($26,789, All periods)
($10,770, All periods)
($127,501, All periods)
a b
c d
Figure 3 (a) Kidney, (b) liver, (c) heart, and (d) lung transplants’ combined mean total costs (2003 $CDN) of the index hospitalization and post-transplantation
follow-up, British Columbia, 1995 to 2003.
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were included in the mean transplantation costs, the use of
monoclonal antibodies may result in higher costs for a small
number of patients and lower costs for the remainder. Fourth,
because they are not recorded in the BC Transplant Society
registry, we were unable to include costs of medications other
than immunosuppressants. For some programs, these costs may
be substantial: for example, for liver transplant recipients, hepa-
titis C is a recurrent problem for which treatment costs are high.
Fifth, we were unable to distinguish between ﬁrst and subsequent
retransplantations; the costs of retransplantations may be higher.
The main strength of the study is that it provides insight into
the magnitude and trends in costs associated with solid organ
transplantations in BC. Moreover, because the costs for all four
programs were calculated using standardized methodology, it
enables the direct comparison of relative costs between programs.
Currently, costs are a major challenge for the successful func-
tioning of transplant centers [41–43], and containing those costs
has become one of the priorities for decision-makers [44,45].
Developing containment strategies requires identifying the
factors associated with high costs. Various factors, including the
patient’s preoperative characteristics, diagnosis and severity of
disease, and presence of postoperative infections and complica-
tions, have been considered as factors that increase the costs of
treatment [8,24,46]. Policymakers and decision-makers seeking
to better understand the deployment of resources may focus on
clinical factors at the time of transplantation and factors that
inﬂuence use and costs of immunosuppressants during the induc-
tion and maintenance phases.
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